<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765256</url>
  </required_header>
  <id_info>
    <org_study_id>823635</org_study_id>
    <nct_id>NCT02765256</nct_id>
  </id_info>
  <brief_title>Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease</brief_title>
  <acronym>Holiday</acronym>
  <official_title>Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crohn's and Colitis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage
      and antibiotics with or without an antifungal) in the management of active Crohn's Disease
      (CD) that is refractory to conventional, immunosuppressive therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in disease activity by Harvey Bradshaw Index</measure>
    <time_frame>15 days</time_frame>
    <description>The primary endpoint will be the change in disease activity, as measured by Harvey-Bradshaw Index (HBI) score, between the enrollment visit and Day 15.All participants who withdraw for any reason prior to day 15 will be considered treatment failures. The Harvey Bradshaw Index is a clinical score which takes into account general well being, degree of abdominal pain, number of liquid stools per day, abdominal physical examination, and Crohn's disease complications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in disease activity by fecal calprotectin (FCP)</measure>
    <time_frame>15 days</time_frame>
    <description>The second primary outcome measure will be the change in disease activity, as measured by fecal calprotectin, between the enrollment visit and day 15. The fecal calprotectin is a stool test which measures intestinal inflammation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in high-sensitivity C-reactive protein (hsCRP)</measure>
    <time_frame>15 days</time_frame>
    <description>A secondary outcome measure will be the change in high-sensitivity C-reactive protein between the enrollment visit and day 15. The high-sensitivity C-reactive protein is a blood test which measures systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the treatment regimen based on medication side effects and/or adverse events (AEs).</measure>
    <time_frame>105 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>400mg orally once daily (Day 1-14)</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>500mg oral suspension 4 times daily (Day 1-14)</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vancocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neomycin</intervention_name>
    <description>neomycin 1000 mg orally three times daily (Days 1-3)</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Neo-Fradin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>ciprofloxacin 750 mg orally twice daily (Day 4-14)</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cipro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol 3350</intervention_name>
    <description>238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Miralax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promethazine</intervention_name>
    <description>PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Phenergan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is capable of giving informed consent

          -  Males or females 18-75 years of age

          -  Normal kidney function (defined by normal serum creatinine [male: &lt;1.27 mg/dL; female:
             &lt;1.03 mg/dL])

          -  Normal aspartate aminotransferase [AST] (&lt;41 U/L), alanine aminotransferase [ALT] (&lt;63
             U/L), and alkaline phosphatase (&lt;126 U/L)

          -  Active CD defined as HBI ≥ 8

          -  CRP &gt; 5 mg/dL or hs-CRP &gt; 10mg/L (or 1mg/dL) or fecal calprotectin (FCP) &gt; - - 400
             mcg/g (within one month of enrollment)

          -  Have been treated with one of the following therapies** for at least 8 weeks with
             primary nonresponse or an initial response, followed by loss of response [LOR]
             (self-reported worsening of symptoms for ≥ 7 days): azathioprine, 6-mercaptopurine,
             methotrexate, adalimumab, certolizumab, golimumab, infliximab, natalizumab,
             vedolizumab, or ustekinumab **These medications must have been administered at
             standard, therapeutic dosages.

        Exclusion Criteria:

          -  Known or suspected stricturing disease producing obstructive symptoms

          -  Active Clostridium difficile infection

          -  Unwillingness to provide informed consent

          -  Allergy or intolerance to the medications used in this study

          -  History of kidney disease

          -  History of liver disease

          -  Pregnant or lactating females

          -  Baseline QTc interval on EKG &gt; 430 in males or &gt; 450 in females

          -  Participants who, in the opinion of the investigator, may be non-compliant with study
             schedules or procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Albenberg, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James D Lewis, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Unmesha Roy Paladhi, BS</last_name>
    <phone>215-746-7138</phone>
    <email>uroy@mail.med.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Nessel, MSS, MLSP</last_name>
    <phone>215-573-6003</phone>
    <email>nessel@mail.med.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Unmesha Roy Paladhi</last_name>
      <phone>215-746-7138</phone>
      <email>uroy@mail.med.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Nessel</last_name>
      <phone>215-573-6003</phone>
      <email>nessel@mail.med.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Lindsey Albenberg</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Neomycin</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

